Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

2.1K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
2.1K
Asthma-II: Pathophysiology and Classification01:26

Asthma-II: Pathophysiology and Classification

4.7K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
4.7K
Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

1.5K
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
1.5K
Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

3.3K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
3.3K
Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

4.2K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
4.2K
Drug Toxicity: Allergic Reactions01:30

Drug Toxicity: Allergic Reactions

84
Drug-related allergies are immune-mediated responses triggered by the administration of pharmacological agents. These hypersensitivity reactions are classified based on the immune mechanisms involved. The four primary types—Type I, II, III, and IV—are mediated by different immunological pathways and exhibit distinct clinical manifestations.Type I Hypersensitivity/ IgE-Mediated Reactions: Immunoglobulin E (IgE) immediately mediates Type I hypersensitivity reactions. Upon initial...
84

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A World Allergy Organization (WAO) manifesto for the worldwide approval of biologic therapies for food allergy.

The World Allergy Organization journal·2025
Same author

Prognostic impact of expression of CD2, CD25, and/or CD30 in/on mast cells in systemic mastocytosis: a registry study of the European Competence Network on Mastocytosis.

Leukemia·2025
Same author

Updated grading system for systemic allergic reactions: Joint Statement of the World Allergy Organization Anaphylaxis Committee and Allergen Immunotherapy Committee.

The World Allergy Organization journal·2024
Same author

WAO consensus on DEfinition of Food Allergy SEverity (DEFASE).

The World Allergy Organization journal·2023
Same author

Symptom control and health-related quality of life in allergic rhinitis with and without comorbid asthma: A multicentre European study.

Clinical and translational allergy·2023
Same author

Clinical review: The suggested management pathway for urticaria in primary care.

Clinical and translational allergy·2022

Related Experiment Video

Updated: Mar 10, 2026

Analyzing the Functions of Mast Cells In Vivo Using 'Mast Cell Knock-in' Mice
09:07

Analyzing the Functions of Mast Cells In Vivo Using 'Mast Cell Knock-in' Mice

Published on: May 27, 2015

11.1K

Mast Cell Clonal Disorders: Classification, Diagnosis and Management.

Merel C Onnes1, Luciana K Tanno2, Joanne N G Oude Elberink1

  • 1Department of Allergology, University Medical Center Groningen, University of Groningen, and Groningen Research Institute for Asthma and COPD, Groningen, The Netherlands.

Current Treatment Options in Allergy
|December 13, 2016
PubMed
Summary

Mast cell clonal disorders involve abnormal mast cell growth due to KIT gene mutations. Treatment varies by severity, with new therapies showing promise for symptom reduction and improved quality of life.

Keywords:
AllergyAnaphylaxisMast cell clonal disordersMastocytosisOsteoporosisTyrosine kinase inhibitors

More Related Videos

Isolation of Peritoneum-derived Mast Cells and Their Functional Characterization with Ca2+-imaging and Degranulation Assays
11:31

Isolation of Peritoneum-derived Mast Cells and Their Functional Characterization with Ca2+-imaging and Degranulation Assays

Published on: July 4, 2018

13.0K
Investigating Mast Cell Secretory Granules; from Biosynthesis to Exocytosis
16:01

Investigating Mast Cell Secretory Granules; from Biosynthesis to Exocytosis

Published on: January 26, 2015

13.8K

Related Experiment Videos

Last Updated: Mar 10, 2026

Analyzing the Functions of Mast Cells In Vivo Using 'Mast Cell Knock-in' Mice
09:07

Analyzing the Functions of Mast Cells In Vivo Using 'Mast Cell Knock-in' Mice

Published on: May 27, 2015

11.1K
Isolation of Peritoneum-derived Mast Cells and Their Functional Characterization with Ca2+-imaging and Degranulation Assays
11:31

Isolation of Peritoneum-derived Mast Cells and Their Functional Characterization with Ca2+-imaging and Degranulation Assays

Published on: July 4, 2018

13.0K
Investigating Mast Cell Secretory Granules; from Biosynthesis to Exocytosis
16:01

Investigating Mast Cell Secretory Granules; from Biosynthesis to Exocytosis

Published on: January 26, 2015

13.8K

Area of Science:

  • Hematology
  • Oncology
  • Genetics

Background:

  • Mast cell clonal disorders stem from somatic mutations in the KIT gene, frequently the D816V mutation.
  • These disorders encompass mastocytosis and monoclonal mast cell activation syndrome, distinguished by clonality levels.
  • Pathological mast cell accumulation and degranulation lead to diverse clinical manifestations.

Approach:

  • Diagnosis relies on identifying mast cell clonality and tissue infiltration (skin and extracutaneous).
  • Treatment strategies are individualized, ranging from symptomatic relief for indolent forms to cytoreductive therapy for advanced disease.
  • Therapeutic choices for advanced mastocytosis are influenced by KIT mutational status.

Key Points:

  • Indolent mastocytosis management focuses on symptom control with antihistamines and treating comorbidities like osteoporosis.
  • Advanced systemic mastocytosis requires cytoreductive therapies to decrease the mast cell burden.
  • Emerging treatments, such as midostaurin, offer potential for symptom alleviation and enhanced patient quality of life.

Conclusions:

  • While curative treatments are currently unavailable, ongoing research is yielding promising therapeutic options.
  • Personalized treatment approaches are crucial for managing the spectrum of mast cell clonal disorders.
  • Targeting KIT mutations and mast cell degranulation represents a key strategy in developing novel therapies.